Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
122.72
+17.78 (16.94%)
At close: Aug 25, 2026, 4:00 PM EDT
122.72
0.00 (0.00%)
After-hours: Aug 25, 2026, 4:10 PM EDT
Inhibrx Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 133.34 | 124.22 | 152.6 | 277.92 | - | 131.3 |
Cash & Short-Term Investments | 133.34 | 124.22 | 152.6 | 277.92 | - | 131.3 |
Cash Growth | -28.53% | -18.60% | -45.09% | - | - | 2.05% |
Accounts Receivable | - | - | 0.2 | 0.78 | 0.24 | - |
Other Receivables | 0.13 | 0.18 | 0.22 | - | 0.01 | - |
Receivables | 0.13 | 0.18 | 0.42 | 0.78 | 0.26 | - |
Inventory | 1.22 | 1.88 | 2 | 9.89 | 0.81 | - |
Prepaid Expenses | 5.91 | 5.01 | 4.19 | 5.67 | 4.53 | - |
Other Current Assets | 1.62 | 1.54 | 1.2 | 1.09 | 0.67 | 7.81 |
Total Current Assets | 142.21 | 132.83 | 160.4 | 295.36 | 6.26 | 139.11 |
Property, Plant & Equipment | 7.24 | 9.27 | 13.54 | 9.37 | 7.22 | - |
Other Long-Term Assets | 4.77 | 4.38 | 6.83 | 3.16 | 3.16 | 11.34 |
Total Assets | 154.22 | 146.48 | 180.77 | 307.89 | 16.65 | 150.45 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.86 | 11.49 | 14.89 | 33.76 | 9.45 | - |
Accrued Expenses | 13.71 | 19.99 | 24.25 | 20.49 | 9.46 | - |
Current Portion of Leases | 2.49 | 2.33 | 1.6 | 2.06 | 1.86 | - |
Other Current Liabilities | - | - | - | - | - | 22.45 |
Total Current Liabilities | 28.06 | 33.8 | 40.73 | 56.31 | 20.77 | 22.45 |
Long-Term Debt | 176.29 | 100.56 | - | 206.97 | - | 70.47 |
Long-Term Leases | 2.85 | 4.13 | 6.45 | 1.11 | 3.17 | - |
Other Long-Term Liabilities | - | - | - | - | - | 5.14 |
Total Liabilities | 207.2 | 138.49 | 47.18 | 264.39 | 23.95 | 98.07 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0.01 | -7.3 | 52.38 |
Additional Paid-In Capital | 263.3 | 254.18 | 239.72 | 657.23 | - | - |
Retained Earnings | -316.28 | -246.19 | -106.13 | -613.73 | - | - |
Shareholders' Equity | -52.98 | 7.99 | 133.58 | 43.5 | -7.3 | 52.38 |
Total Liabilities & Equity | 154.22 | 146.48 | 180.77 | 307.89 | 16.65 | 150.45 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 181.63 | 107.01 | 8.05 | 210.14 | 5.03 | 70.47 |
Net Cash (Debt) | -48.28 | 17.21 | 144.55 | 67.78 | -5.03 | 60.83 |
Net Cash Growth | - | -88.09% | 113.25% | - | - | -38.81% |
Net Cash Per Share | -3.10 | 1.11 | 9.65 | 5.75 | -0.13 | 1.60 |
Filing Date Shares Outstanding | 14.72 | 14.61 | 14.48 | 13.53 | 43.27 | 38.58 |
Total Common Shares Outstanding | 14.71 | 14.58 | 14.48 | 13.53 | 43.27 | 38.58 |
Working Capital | 114.15 | 99.03 | 119.67 | 239.05 | -14.51 | 116.66 |
Book Value Per Share | -3.60 | 0.55 | 9.23 | 3.22 | -0.17 | 1.36 |
Tangible Book Value | -52.98 | 7.99 | 133.58 | 43.5 | -7.3 | 52.38 |
Tangible Book Value Per Share | -3.60 | 0.55 | 9.23 | 3.22 | -0.17 | 1.36 |
Machinery | 10.07 | 10.08 | 10.31 | 9.02 | 7.55 | - |
Construction In Progress | - | - | - | 3.59 | - | - |
Leasehold Improvements | 0.8 | 0.8 | 0.8 | 0.44 | 0.44 | - |